Large clinical research organisations (CROs) continue to merge to create a new category of mega CROs. While these are ideally placed to serve Big Pharma, they move away from small pharma and biotech businesses, which continue to grow in importance to the UK pharma sector. This is making room for small and mid-sized CROs to become the partner of choice for these businesses.